GlobeNewswire by notified

Oxurion Receives Transparency Notifications Based on New Denominator

Share

Leuven, BELGIUM, Boston, MA, US November 17, 2022 –8 AM CETOxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows:

Following the issuance of new shares pursuant to the Capital Commitment entered into with Negma Group Ltd., the updated denominator for transparency notifications was 109,075,765 shares as of November 11, 2022: Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA | Oxurion NV)

Oxurion received transparency notification from Negma Group indicating that as of November 16, it holds 0 common shares. Oxurion also received transparency notification from Fidelity Management & Research Company LLC that their 3,128,819 common shares have crossed below the lowest threshold (3%) by virtue of a downward passive crossing.

In addition, by virtue of a downward passive crossing, the following thresholds have been crossed:

  • Novartis Pharma AG’s 2,177,226 shares have crossed below the lowest threshold (3%)
  • Philippe Vlerick/Balderma SA’s 3,580,787 shares have crossed below the lowest threshold (3%)
  • Thomas M. Clay’s 4,542,110 shares have crossed below the 5% threshold

Content of the latest Negma Group Ltd. Notification

Reason of the notification

Acquisition or disposal of voting securities or voting rights

Notifications by

A person that notifies alone

Threshold that is crossed

Downward crossing of the lowest threshold

Denominator

109,075,765

Chain of controlled undertakings through which the holding is effectively held

Not applicable

Notified details

See Annex 1 for this and prior transparency notification of November

Content of the Fidelity Management & Research Company LLC Notification

Reason of the notification

Passive crossing of a threshold
Downward crossing of the lowest threshold

Notifications by

A parent undertaking or a controlling person

Threshold that is crossed

3%

Denominator

109,075,765

Notified details

See Annex 2

Chain of controlled undertakings through which the holding is effectively held

Fidelity Management & Research Company LLC is controlled by FMR LLC.

FMR LLC is not a controlled entity

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV
Tom Graney
Chief Executive Officer
Tel: +32 16 75 13 10
tom.graney@oxurion.com



Michael Dillen
Chief Business Officer
Tel: +32 16 75 13 10
michael.dillen@oxurion.com

US
Conway Communications
Beth Kurth
bkurth@conwaycommsir.com





ICR Westwicke
Christopher Brinzey
Tel: +1 617 835 9304
Chris.Brinzey@westwicke.com

ANNEX 1

Negma notification of November 16, 2022

A)VotingrightsPreviousnotificationAfterthetransaction
#ofvotingrights#ofvotingrights%ofvotingrights


Holders of voting rights


Linked to securities
Not linked to the securities Linked to securities Not linked to the securities
Elaf Gassam 0 0





-
Negma Group Investment Ltd. 0 0 -
Negma Group Ltd. 16,250,000 0 -
Subtotal 16,250,000 0 +

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

B)EquivalentfinancialinstrumentsAfterthetransaction





Holdersofequivalentfinancialinstruments






Typeoffinancialinstrument






Expirationdate




Exerciseperiodordate


#ofvotingrightsthat may beacquired if theinstrumentisexercised






%ofvotingrights






Settlement
+
TOTAL00.00%

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.Thetotalswillbeupdatedonceyouhaveclickedon<CALCULATE>



TOTAL(A& B)


#ofvotingrights


%ofvotingrights
CALCULATE00.00%

Negma notification of November 8, 2022

A)VotingrightsPreviousnotificationAfterthetransaction
#ofvotingrights#ofvotingrights%ofvotingrights


Holders of voting rights


Linked to securities
Not linked to the securities Linked to securities Not linked to the securities
02/11/2022: Negma Group Ltd. Threshold: + 15 % 0 15,000,000 16.16%







-
03/11/2022: Negma Group Ltd. Threshold: - 10 % 8,828,255 -
04/11/2022: Negma Group Ltd 8,750,000 -
7/11/2022: Negma Group Ltd. Threshold: - 3 % (see section 13) 0 -
Subtotal 15,000,000 16.16% +
TOTAL15,000,000016.16%0.00%


B)EquivalentfinancialinstrumentsAfterthetransaction





Holdersofequivalentfinancialinstruments




Typeoffinancialinstrument






Expirationdate




Exerciseperiodordate


#ofvotingrightsthat may beacquired if theinstrumentisexercised






%ofvotingrights






Settlement
+
TOTAL00.00%




TOTAL(A& B)


#ofvotingrights


%ofvotingrights
CALCULATE15,000,00016.16%

ANNEX 2

B)EquivalentfinancialinstrumentsAfterthetransaction





Holdersofequivalentfinancialinstruments






Typeoffinancialinstrument






Expirationdate




Exerciseperiodordate


#ofvotingrightsthat may beacquired if theinstrumentisexercised






%ofvotingrights






Settlement
Fidelity Management & Research Company LLC Stock Loan 90,401 0.08% physical +
TOTAL90,4010.08%


TOTAL(A&B)


#ofvotingrights


%ofvotingrights
CALCULATE3,128,8192.87%

________

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Brookfield to Present at the Goldman Sachs 2022 US Financial Services Conference28.11.2022 22:01:00 CET | Press release

BROOKFIELD, NEWS, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (NYSE: BAM, TSX: BAM.A) today announced that Bruce Flatt, Chief Executive Officer, is scheduled to present at the Goldman Sachs US Financial Services Conference on Wednesday, December 7, 2022, at 1:40pm ET. A live webcast will be available on the Brookfield website at https://bam.brookfield.com/news-events/events. For those unable to join the live webcast, a recording will be available on Brookfield’s website shortly after the event. About Brookfield Brookfield (NYSE: BAM, TSX: BAM.A) is a leading global alternative asset manager with over $750 billion of assets under management across real estate, infrastructure, renewable power and transition, private equity and credit. Brookfield owns and operates long-life assets and businesses, many of which form the backbone of the global economy. Utilizing its global reach, access to large-scale capital and operational expertise, Brookfield offers a range of alt

Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US28.11.2022 22:00:00 CET | Press release

New patent granted in the United States by the USPTO covers the use of lanifibranor for the potential treatment of cirrhotic patients at risk of progressing from compensated stage to decompensated stage This patent strengthens and expands the intellectual property protection of lanifibranor in the United States particularly for use for patients with cirrhotic NASH Daix (France), Long Island City (New York, United States), November 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today announced that the United States Patent and Trademark Office (“USPTO”) granted a patent (U.S. Patent No. 11,504,380) that protects the use of lanifibranor for the treatment of cirrhotic patients at risk of progressing from compensated stage to decompensa

EYES ON IRAN ART ACTIVATION FACES THE U.N. IN NEW YORK28.11.2022 21:04:15 CET | Press release

AN EVENT MARKED THE OPENING FEATURING HILLARY RODHAM CLINTON, GISSOU NIA,SHEIDA SOLEIMANI, SHIRIN NESHAT with SPECIAL PERFORMANCE BY JON BATISTE NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Iranian artists Sheida Soleimani, Aphrodite Désirée Navab, Z, Icy and Sot, Shirin Neshat, Mahvash Mostala, Sepideh Mehraban, and Shirin Towfiq, alongside artists Hank Willis Thomas and JR, activate New York’s FDR Four Freedoms State Park with a provocative multi-day and multi-media art installation facing the United Nations entitled Eyes on Iran, November 28, 2022 - January 1, 2023. Timed for the U.N. initiative, 16 Days of Activism Against Gender-Based Violence, the installations are focused on the power of collective sight, with eyes facing the U.N., signifying the world’s eyes on Iran. 'Eyes in the Sky' flying billboards featuring artworks by Thomas and Mostala will fly on December 3 in New York City and on November 28 and 30 in Miami. An interactive installation by artist JR will take place on

PRESS RELEASE: BIGBEN: 2022-23 HALF-YEAR RESULTS28.11.2022 18:09:56 CET | Press release

Press release Lesquin, 28 November 2022 18:00hrs 2022-23 HALF-YEAR RESULTS UP 138.5 M€ SALES (+11.6%)11.8 M€ CURRENT OPERATING RESULT (+19.6%)7.6 M€ NET RESULT (+9.6%) STRONG GROWTH AMBITION REITERATED FOR FY2023-24 CONTINUATION OF THE GAMES PUBLISHING MOMENTIUMENCOURAGING OUTLOOK FOR THE AUDIOVIDEO/TELCO BUSINESS BIGBEN INTERACTIVE (ISIN FR0000074072) today releases its audited consolidated results for 1st Half Year 2022-23 (from April 1, 2022 to September 30, 2022) as approved by its Board of directors on 28 November 2022. Consolidated in M€ - IFRS09/202209/2021 ChangeSales138.5124.2+11.6%Gross margin (1) In % of Sales EBITDA(2) In % of Sales 64.8 46.8% 28.3 20.4% 51.4 41.4% 24.6 19.8%+26.0% +15.2%Current operating income EBITA In % of Sales Non recurrent items 11.8 8.5% (1.4)9.9 8.0% (5.8) +19.6% Operating income In % of Sales 10.5 7.6%4.1 3.3%+153.6%Financial result(0.3)4.8 Earnings before tax In % of Sales 10.2 7.4%9.0 7.2%+13.5%Tax(2.6)(2.0)Net result for the period In % of Sales